瑞马唑仑的药理特点、安全性及联合用药研究进展  

Research progress on pharmacological characteristics,safety and drug combination of remimazolam

作　　者：贾涛 刘辉[1] 滕金亮[1] JIA Tao;LIU Hui;TENG Jinliang(Dept.of Anesthesiology,the First Affiliated Hospital of Hebei North University,Hebei Zhangjiakou 075000,China;Graduate School of Hebei North University,Hebei Zhangjiakou 075000,China)

机构地区：[1]河北北方学院附属第一医院麻醉科,河北张家口075000 [2]河北北方学院研究生院,河北张家口075000

出　　处：《中国药房》2023年第8期1020-1024,共5页China Pharmacy

基　　金：张家口市重点研发计划项目(No.1921060D)。

摘　　要：瑞马唑仑(甲苯磺酸盐)是一种新型的超短效水溶性苯二氮类镇静药,可用于常规胃镜和结肠镜检查镇静以及全身麻醉诱导和维持,于2019年12月26日在我国上市,其上市打破了国内30年无镇静创新药上市的局面。本文对瑞马唑仑的药理特点、安全性和联合用药情况进行综述。瑞马唑仑具有清除率高、作用时间短、恢复快、血流动力学稳定、呼吸抑制作用小等优点,不依赖于肝肾代谢,可被氟马西尼快速拮抗,对患者认知功能影响小。瑞马唑仑在与丙泊酚、艾司氯胺酮等静脉麻醉药和舒芬太尼、瑞芬太尼、阿芬太尼等阿片类镇痛药联合用药方面均显示出较好的呼吸循环稳定性,还有苏醒快、恢复快等优点,但其安全性仍需在临床使用中进一步监测和探究。Remimazolam(toluenesulfonate)is a new type of ultra short-acting water-soluble benzodiazepine sedative-hypnotic drug,which was launched in China on December 26,2019,for sedation during routine gastroscopy and colonoscopy as well as induction and maintenance under general anesthesia,breaking a 30-year period in which no innovative sedation drugs were marketed in China.This article reviewed the pharmacological characteristics,safety and combined use of remimazolam.Remimazolam had the advantages of high clearance rate,short action time,rapid recovery,stable hemodynamics,and low respiratory inhibition.It is independent of liver and kidney metabolism,and can be quickly antagonized by flumazenil,with little impact on the cognitive function of patients.Remimazolam has shown good respiratory and circulatory stability in combination with intravenous anesthetics such as propofol and esketamine,and opioid analgesics such as sufentanil,remifentanil,and alfentanil,as well as advantages such as rapid awakening and recovery.However,its safety still needs to be further monitored and explored during clinical use.

关 键 词：瑞马唑仑 药理特点 安全性 联合用药 临床麻醉 

分 类 号：R971.2[医药卫生—药品]